RJA
SXTP icon

Raymond James & Associates’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Raymond James & Associates’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-42
Closed -$2.53K – 4100
2024
Q2 		$2.53K Buy
+42
New +$2.67K ﹤0.01% 3949

Other funds holding SXTP

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SHF
Safe Harbor Fiduciary Pensacola, Florida $105M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James & Associates's SXTP Position: Q3 2024 in Review

Raymond James & Associates sold out of 60 Degrees Pharmaceuticals (SXTP) in Q3 2024, closing a stake of 42 shares — an estimated $2.53K sold.

Raymond James & Associates first reported a position in SXTP in Q2 2024 and held it in 1 quarter. The position peaked at $2.53K in Q2 2024. 6 funds tracked by Wall St. Rank hold SXTP as of Q3 2024.

  • Raymond James & Associates reported no remaining 60 Degrees Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 42 60 Degrees Pharmaceuticals shares in Q3 2024, an estimated $2.53K.
  • Raymond James & Associates first reported a position in 60 Degrees Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Raymond James & Associates's 60 Degrees Pharmaceuticals position peaked at $2.53K in Q2 2024.
  • 6 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.